INSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION

Size: px
Start display at page:

Download "INSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION"

Transcription

1 INSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION Jaiwant Rangi, MD, FACE Nov 10 th 2018

2 DISCLOSURES Speaker Novo Nordisk Sanofi-Aventis Boheringer Ingleheim Merck Abbvie Abbott

3 T1DM: DESTRUCTION OF THE PANCREAS Type 1 Diabetes is caused by the autoimmune destruction of insulin producing ß-cells Antigen TCR T Cell T Cell ß-cells T-cells mediated killing of ß-cells

4 T2DM: RESISTANCE TO INSULIN Food Intake Fat cells Muscle cells Liver Carbohydrate absorbed Insulin Elevated Blood Glucose Pancreas

5 INSULIN ACTION Glucose uptake Lipolysis Fat storage Fat cells Muscle cells Liver Glucose production Glucose storage Carbohydrate absorbed Insulin Elevated Blood Glucose Pancreas

6 INSULIN RESISTANCE Fat cells Muscle cells Liver Carbohydrate absorbed Insulin Elevated Blood Glucose Pancreas

7

8 CASE #1 48 year old man with Type 2 DM x 12 years. Current DM meds Metformin 1000 mg BID Sitagliptin 100 mg QD Glipizide 10 mg BID On ACE-I for Hypertension and Statin for elevated Cholesterol

9 CASE #1 PE: Obese, 5 10, 245 lbs. BMI PE otherwise unremarkable HbA1C 8.7 % Fasting BG levels between What is the next step for DM management?

10

11

12 BARRIERS TO STARTING INSULIN Fear of needles Fear of hypoglycemia No time to learn about insulin Concerns about side effects of insulin History of family member that was on insulin and then Feeling like failure in terms of diabetes

13 INSULIN DELIVERY DEVICES

14 STARTING BASAL INSULIN AACE Guidelines: Pick a starting dose for basal insulin A1c < 8 % units A1c > 8 % units I often start at either 10 or 20 units or based on weight for morbidly obese patients otherwise it takes long to titrate

15 STARTING BASAL INSULIN Titration: Increase insulin by 2 units 2 x per week (pick days) until fasting blood glucose levels are to goal Decrease by 2 units if hypoglycemia Goal Blood Sugar: Generally mg/dl Higher risk of hypoglycemia mg/dl Max dose insulin: 40 units is a reasonable start Allows patients to be comfortable increasing dose

16 STARTING BASAL INSULIN Start insulin Glargine 20 units between 9-11 PM Check FSBG levels every morning Goal fasting BG: mg/dl Every Wed and Sat review your blood glucose levels and if not to goal, increase Glargine dose by 2 units (example increase from 20 to 22 units daily) Once you reach Glargine 40 units please contact provider

17 CASE #1 CONT. Started on Glargine 20 units Goal fasting BG mg/dl Titrate 2 x per week Follow up appointment in 1 month Glargine increased to 32 units Fasting BG usually around mg/dl Had one episode of low BG with symptoms, checked FSBG and it was 82 mg/dl Stopped increasing his dose after that low

18 CASE #2 82 year old man with Type 2 Diabetes for 30 years. He lives by himself and is very worried about low blood glucose levels Current DM meds: Metformin 1000 mg BID Degludec 24 units at night Empagliflozin 10 mg QD HbA1c of 8.4 % at appointment today. Checks FSBG once per day. Fasting range mg/dl What are your options for next steps?

19

20 CASE #2 Options include: GLP1-RA SU Prandial Insulin DPP4 inhibitor TZD If hypoglycemia is his main concern, what options would you consider?

21 CASE #2 CONT. Decided to start on a GLP1 RA Options: Once daily injection (Liraglutide/Victoza) Once weekly injection (Duglaglutide / Trulicity, Exenatide/Bydureon, Semaglutide / Ozempic) Combination (Soliqua 100/33 Glargine and Lixisenatide or Xultrophy 100/3.6 Degludec and Liraglutide)

22 CASE #3 62 year old woman with a history type 2 DM for 14 years She struggles with her diet and finds the higher carbohydrate options easiest while at work Current DM meds: Toujeo (U300 Glargine) 56 units Dulaglitide/Trulicity 1.5 mg weekly Canagliflozin / Invokana 300 mg QD Repaglinide / Prandin 1 mg 1-2 tabs before meals

23 Case #3 cont. HbA1c 10.0 %!! Forgot her BG meter, but does try to check her FSBG 1-2 times per week fasting Reports good BG levels, usually around mg/dl in the morning Admits, she does miss the Repaglinide / Prandin several times per week

24 Case #3 cont. CGM placed and she returns in 2 weeks with data

25 INSULIN OPTIONS

26 BASAL / BOLUS INSULIN

27 BASAL/BOLUS INSULIN Basal Insulin Long acting insulin to help lower fasting and between meal BG levels Bolus Insulin Prandial Insulin (meal time) Short acting insulin taken before a meal to prevent a post prandial spike Correctional Insulin Short acting insulin, extra insulin taken to correct a high BG level

28 CASE #3 CONT. Will start short acting insulin prior to each meal Current Basal insulin dose is 54 units. But her BG is dropping mg/dl overnight Decrease Basal Insulin to 40 units Start prandial insulin with meal(s)

29 CASE #3 Basal plus one: Start 10 % of basal or 5 units with one meals Basal / Bolus: Start 50 % basal and 50 % bolus Total daily insulin dose: units/kg

30 CASE #3 CONT Decrease Toujeo dose to 40 units Start Lispro 10 units with each meal Encouraged her to keep CHO consistent around gm. per meal Add correction insulin if BG above 150 per sliding scale

31 CASE #3 CONT. Blood Sugar: Insulin Dose: <70 No insulin, 15 gm of CHO and repeat units units units units > units

32 CASE #3 She does not like carrying her Sliding Scale around, how else can she determine her insulin doses? CHO counting working with a dietician, patient learns to count CHO and determine insulin dose based on CHO content of the meal example: 1 unit of insulin per 5 gm. of CHO Correction or sensitivity factor determine decrease in BG per unit of insulin example: 1 unit per 25 mg/dl above target of 150 mg/dl

33 CASE #4 67 year old man with Type 2 DM x 22 years presents to your office. His complications include nephropathy and neuropathy Rx History: He has been on insulin for over 15 years. No oral agents due to renal disease and intolerance Current RX: Glargine 80 units Lispro 25 units with meals

34 CONCENTRATED INSULIN Is he a good candidate for a concentrated insulin? What options are available for concentrated Insulin's?

35 CONCENTRATED INSULIN Candidates: Insulin resistance: on medications such as steroids Genetic forms of insulin resistance On more than 100 units per day of insulin Presence of insulin antibodies Type 1 DM with obesity or overweight

36 CONCENTRATED INSULIN OPTIONS U500 syringe and vial remember dose is 5 X amount seen on the insulin syringe U500 Pen dose is in units U300 Glargine (Toujeo) Solostar pen U200 Degludec (Tresiba) - Flexpen U200 Lispro (Humalog) Kwik pen

37 INTEGRATED PUMP/CGM SYSTEMS Minimum 670G is the first hybrid closed loop system Data from the CGM is transmitted to the pump and the basal rate is adjusted Patient must still enter CHO and corrections More integrated systems to come in the next 1-2 years

38 CASE #4 CONT. Started on U-300 Glargine and U-200 Humalog with meals Advantages: Smaller injection volume (more comfortable) Pens last longer (and less waste) Potentially less risk of hypoglycemia (especially overnight) Less time dependent (any time of day dosing)

39 CASE #5 24 year old woman with Type 1 Diabetes working at a start up just moved to the area DM diagnosed at age 9. No complications HbA1c 8.2 % Current insulin doses: Degludec: 12 units AM, 8 units PM Lispro: 1 unit per 14 gm of carbohydrate 1 unit per 20 mg/dl above target of 120 mg/dl She is interested in learning more about technology for Diabetes what are her options?

40 TECHNOLOGY Insulin Delivery Systems Blood glucose monitoring Meters Continuous Glucose Sensors

41 CONTINUOUS SUBCUTANEOUS INSULIN INFUSION (CSII) Catheter is placed subcutaneously and connected to an electronic pump. Pump delivers low levels of basal rate short acting insulin (rates can vary during the day). Patient can give boluses for meals and corrections for high blood glucose levels.

42 REAL TIME CONTINUOUS GLUCOSE SENSORS Subcutaneous catheter inserted every 7-10 days. Interstitial fluid BG measurement every 5 minutes. Alarms can be set for highs and lows. Currently available CGMs: Medtronic Minimed Dexcom G5 (G6 any day now) Abbott Freestyle Libre

43 REAL TIME CONTINUOUS GLUCOSE SENSORS

44 CASE #5 CONT. Patients decides to start on a CGM to help warn her about hypoglycemia Finds that she was having nocturnal hypoglycemia and rebound fasting high BG levels Decreased her Basal Insulin Discovered a lot of after meal highs, needs to adjust the timing of her meal time insulin She is considering her options for a closed loop system in the future

45 Thank you! Contact information: Office:

Insulin Initiation and Intensification. Disclosure. Objectives

Insulin Initiation and Intensification. Disclosure. Objectives Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School

More information

Learning Objectives. Are you ready for more insulin formulations?

Learning Objectives. Are you ready for more insulin formulations? Are you ready for more insulin formulations? Shara Elrod, PharmD, BCACP, BCGP Learning Objectives Review pharmacology and dosing of new insulin formulations Compare and contrast new insulin formulations

More information

New Therapies for Diabetes Management: Hope or Headache?

New Therapies for Diabetes Management: Hope or Headache? New Therapies for Diabetes Management: Hope or Headache? Elizabeth Stephens, MD, FACP PMG- Endocrinology Elizabeth.Stephens@providence.org November 2018 Disclosures None 1 Objectives Discussion of 3 rd

More information

Individualizing Care for Patients with Type 2 Diabetes

Individualizing Care for Patients with Type 2 Diabetes Individualizing Care for Patients with Type 2 Diabetes Disclosures Speaker: AstraZeneca, Novo Nordisk, BI/Lilly, Valeritas, Takeda Advisor: Tandem Diabetes, Sanofi Objectives Develop individualized approaches

More information

The Management of Diabetes in Primary Care Kelly Krawtz, PharmD, BCPS, BCACP

The Management of Diabetes in Primary Care Kelly Krawtz, PharmD, BCPS, BCACP The Management of Diabetes in Primary Care Kelly Krawtz, PharmD, BCPS, BCACP Objectives Explain the current pharmacologic options for the management of diabetes Describe the latest technologies available

More information

INSULIN 101: When, How and What

INSULIN 101: When, How and What INSULIN 101: When, How and What Alice YY Cheng @AliceYYCheng Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form

More information

Mixed Insulins Pick Me

Mixed Insulins Pick Me Mixed Insulins Pick Me Alvin Goo, PharmD Clinical Associate Professor University of Washington School of Pharmacy and Department of Family Medicine Objectives Critically evaluate the evidence comparing

More information

Update on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015

Update on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015 Update on Therapies for Type 2 Diabetes: 2015 Angela D. Mazza, DO July 31, 2015 Objectives To present the newer available therapies for the management of T2D To discuss the advantages and disadvantages

More information

Intensification of Diabetic Therapy. Case studies

Intensification of Diabetic Therapy. Case studies Intensification of Diabetic Therapy Case studies Patient #1 1 st visit: 64 year old male, H/O prediabetes, lost weight 280 lbs. to 240 lbs. ER for dental abscess, glucose >300 A1C 11.4%, no diabetic medication,

More information

Type 2 Diabetes Mellitus Insulin Therapy 2012

Type 2 Diabetes Mellitus Insulin Therapy 2012 Type 2 Diabetes Mellitus Therapy 2012 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Preparations Onset Peak Duration

More information

Let s not sugarcoat it! Update on Pharmacologic Management of Type II DM

Let s not sugarcoat it! Update on Pharmacologic Management of Type II DM Let s not sugarcoat it! Update on Pharmacologic Management of Type II DM Gregory Castelli, PharmD, BCPS, BC-ADM Clinical Pharmacist UPMC St. Margaret Objectives By the end of this presentation, participants

More information

INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE

INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE OBJECTIVES DESCRIBE INSULIN, INCLUDING WHERE IT COMES FROM AND WHAT IT DOES STATE THAT

More information

Clinical Cases in Diabetes Management. Joseph Cook D.O.

Clinical Cases in Diabetes Management. Joseph Cook D.O. Clinical Cases in Diabetes Management Joseph Cook D.O. Objectives State the prevalence of Diabetes Mellitus in Ohio State the percentage of diabetic patients in the U.S. treated by Primary Care Physicians

More information

Advances in Diabetes Care Technologies

Advances in Diabetes Care Technologies 1979 Advances in Diabetes Care Technologies 2015 Introduction Insulin pump use: ~ 20% - 30% of patients with T1DM < 1% of insulin-treated patients with T2DM 2007 FDA estimates ~375,000 insulin pumps for

More information

Physiology of Normoglycemia

Physiology of Normoglycemia Case 1 45 year-old male patient seen at the clinic (Medicine). Workplace stress (financial analyst); occasionally goes jogging. Two-year duration of T2DM. No previous cardiovascular events. Coexisting

More information

Update on New Basal Insulins and Combinations: Starting, Titrating and Adding to Therapy

Update on New Basal Insulins and Combinations: Starting, Titrating and Adding to Therapy Update on New Basal Insulins and Combinations: Starting, Titrating and Adding to Therapy Jerry Meece, BPharm, CDE, FACA, FAADE Director of Clinical Services Plaza Pharmacy and Wellness Center Gainesville,

More information

Diabetes and Technology. Saturday, September 9, 2017 Aimee G sell, APRN, ANP-C, CDE

Diabetes and Technology. Saturday, September 9, 2017 Aimee G sell, APRN, ANP-C, CDE Diabetes and Technology Saturday, September 9, 2017 Aimee G sell, APRN, ANP-C, CDE Disclosure Speaker s Bureau: Janssan Pharmaceuticals Current Technology V-Go by Valeritas Continuous Sensors (personal

More information

Diabetes Update Bryan Heart Conference September 5, 2015 Shannon Wakeley, MD. Disclosures. Objectives 9/1/2015

Diabetes Update Bryan Heart Conference September 5, 2015 Shannon Wakeley, MD. Disclosures. Objectives 9/1/2015 Diabetes Update Bryan Heart Conference September 5, 2015 Shannon Wakeley, MD Disclosures I speak on behalf of the following companies: Astra Zeneca, Boehringer Ingelheim, Johnson & Johnson, Sanofi and

More information

Management of Type 2 Diabetes Mellitus. Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism

Management of Type 2 Diabetes Mellitus. Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism Management of Type 2 Diabetes Mellitus Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism Disclosures Working for Intermountain Healthcare Some of the views represented are the opinion of ABIM-certified

More information

Images have been removed from the PowerPoint slides in this handout due to copyright restrictions. Insulins. Rapid Short Intermediate Long Mix

Images have been removed from the PowerPoint slides in this handout due to copyright restrictions. Insulins. Rapid Short Intermediate Long Mix Diabetes Medications Diabetes Medications Type 1 Insulin is needed Type 2 Oral Diabetes Medications Or Oral Diabetes Medications plus Insulin Or Insulin Alone Diabetes Medications Secretagogues Glipizide

More information

Incorporating CGM Into Clinical Decision Making. Etie Moghissi, MD, FACE Clinical Associate Professor, David Geffen School of Medicine UCLA

Incorporating CGM Into Clinical Decision Making. Etie Moghissi, MD, FACE Clinical Associate Professor, David Geffen School of Medicine UCLA Incorporating CGM Into Clinical Decision Making Etie Moghissi, MD, FACE Clinical Associate Professor, David Geffen School of Medicine UCLA 1 Limitations of Current Glucose Monitoring Methods A1c Standard

More information

Tips and Tricks for Starting and Adjusting Insulin. MC MacSween The Moncton Hospital

Tips and Tricks for Starting and Adjusting Insulin. MC MacSween The Moncton Hospital Tips and Tricks for Starting and Adjusting Insulin MC MacSween The Moncton Hospital Progression of type 2 diabetes Beta cell apoptosis Natural History of Type 2 Diabetes The Burden of Treatment Failure

More information

How they work and when to take them. Diabetes Medications

How they work and when to take them. Diabetes Medications How they work and when to take them Diabetes Medications BIGUANIDES Metformin Actions Slows down the release of glucose from the liver. Helps the bodies cells become more sensitive to insulin. Pros Weight

More information

Inpatient Glycemic Management:

Inpatient Glycemic Management: Disclosure to Participants Conflict of Interest (COI) and Financial Relationship Disclosures: Dr. Seley attended Advisory Board Meeting: Alliance (Boehringer-Ingelheim/Lilly) Bayer Diabetes Care Sanofi

More information

What s New in Type 2 Diabetes? 2018 Diabetes Updates

What s New in Type 2 Diabetes? 2018 Diabetes Updates What s New in Type 2 Diabetes? 2018 Diabetes Updates Gretchen Ray, PharmD, PhC, BCACP, CDE Associate Professor, UNM College of Pharmacy January 28, 2018 gray@salud.unm.edu OBJECTIVES Describe the most

More information

Using Insulin in the Primary Care Setting: Interactive Cases

Using Insulin in the Primary Care Setting: Interactive Cases Using Insulin in the Primary Care Setting: Interactive Cases Irl B. Hirsch, MD University of Washington School of Medicine Dualities (Nov, 2011) Research Grants: sanofi-aventis, Novo Nordisk, Halozyme,

More information

Rebecca Newberry APRN MS CDE

Rebecca Newberry APRN MS CDE Current Diabetes Medications Nursing Implications and Applications Rebecca Newberry APRN MS CDE Methodist Center for Diabetes and Nutritional Health Disclosures Objectives Speakers Bureaus/Consulting Board

More information

7/8/2016. Sol Jacobs MD, FACE Division of Endocrinology Emory University School of Medicine

7/8/2016. Sol Jacobs MD, FACE Division of Endocrinology Emory University School of Medicine Sol Jacobs MD, FACE Division of Endocrinology Emory University School of Medicine Participation in investigator initiated clinical research supported by: Merck Boehringer Ingelheim Novo Nordisk Astra Zeneca

More information

Making Sense of New DM Therapies and Technologies

Making Sense of New DM Therapies and Technologies Making Sense of New DM Therapies and Technologies Sandra Indacochea Sobel, MD Clinical Assistant Professor of Medicine Clinical Chief of Endocrinology, UPMC Mercy Division of Endocrinology, Diabetes, and

More information

Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM

Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM Beyond Basal Insulin: Intensification of Therapy Jennifer D Souza, PharmD, CDE, BC-ADM Disclosures Jennifer D Souza has no conflicts of interest to disclose. 2 When Basal Insulin Is Not Enough Learning

More information

What the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin

What the Pill Looks Like. How it Works. Slows carbohydrate absorption. Reduces amount of sugar made by the liver. Increases release of insulin Diabetes s Oral s - Pills These are some of the pills that are currently available in Canada to treat diabetes. Each medication has benefits and side effects you should be aware of. Your diabetes team

More information

Initiation and Titration of Insulin in Diabetes Mellitus Type 2

Initiation and Titration of Insulin in Diabetes Mellitus Type 2 Initiation and Titration of Insulin in Diabetes Mellitus Type 2 Greg Doelle MD, MS April 6, 2016 Disclosure I have no actual or potential conflicts of interest in relation to the content of this lecture.

More information

Disclosure 1/16/2017. Michael R. Brennan D.O., M.S., F.A.C.E Director Beaumont Endocrine Center Chief of Endocrine Beaumont Grosse Pointe 1/16/2017 2

Disclosure 1/16/2017. Michael R. Brennan D.O., M.S., F.A.C.E Director Beaumont Endocrine Center Chief of Endocrine Beaumont Grosse Pointe 1/16/2017 2 Therapy For Diabetes Michigan Association of Osteopathic Family Physicians Mid-Winter Family Medicine Update Shanty Creek Resort, MI January 19-22nd 2017 Michael R. Brennan D.O., M.S., F.A.C.E Director

More information

GLP-1 receptor agonists for type 2 diabetes currently available in the U.S.

GLP-1 receptor agonists for type 2 diabetes currently available in the U.S. GLP-1 receptor agonists for type 2 diabetes currently available in the U.S. GLP-1 agonists are a class of antidiabetic agents that mimic the actions of the glucagon-like peptide. GLP-1 is one of several

More information

Learning Objectives. Impact of Diabetes II UPDATES IN TYPE 2 DIABETES. David Doriguzzi, PA-C

Learning Objectives. Impact of Diabetes II UPDATES IN TYPE 2 DIABETES. David Doriguzzi, PA-C UPDATES IN TYPE 2 DIABETES David Doriguzzi, PA-C Learning Objectives Upon completion of this educational activity, the participant should be able to: Overcome barriers and attitudes that limit Clinician/Patient

More information

What s New in Type 2 Diabetes? 2018 Diabetes Updates

What s New in Type 2 Diabetes? 2018 Diabetes Updates What s New in Type 2 Diabetes? 2018 Diabetes Updates Jessica Conklin, PharmD, PhC, BCACP, CDE, AAHIP Associate Professor, UNM College of Phar macy jeconklin@salud.unm.edu Luis Gonzales, PharmD, PhC UNM

More information

BEST 4 Diabetes. Optimisation of insulin module

BEST 4 Diabetes. Optimisation of insulin module BEST 4 Diabetes Optimisation of insulin module Confidence and competence Where would you rate yourself? Why do all of our patient not achieve optimal blood glucose control? Insulin Therapy Goals and Purpose

More information

Pharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17

Pharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17 Pharmacology Updates Quang T Nguyen, FACP, FACE, FTOS 11/18/17 14 Classes of Drugs Available for the Treatment of Type 2 DM in the USA ### Class A1c Reduction Hypoglycemia Weight Change Dosing (times/day)

More information

BEST 4 Diabetes. Optimisation of insulin module

BEST 4 Diabetes. Optimisation of insulin module BEST 4 Diabetes Optimisation of insulin module Confidence and competence Where would you rate yourself? Why do all of our patient not achieve optimal blood glucose control? Insulin Therapy Goals and Purpose

More information

2018 Diabetes Summit Managing Diabetes: An Art and a Science

2018 Diabetes Summit Managing Diabetes: An Art and a Science 2018 Diabetes Summit Managing Diabetes: An Art and a Science Natasha Petry, PharmD, BCACP NDSU College of Health Professions, School of Pharmacy, Department of Pharmacy Practice Patient-Centered Medical

More information

Advances in Diabetes Care Technologies

Advances in Diabetes Care Technologies 1979 Advances in Diabetes Care Technologies 2015 Introduction Roughly 20% - 30% of patients with T1DM and fewer than 1% of insulin-treated patients with T2DM use an insulin pump In 2007, the US FDA estimated

More information

Objectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors

Objectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors No disclosure Objectives Recognize all available medical treatment options for diabetes Individualize treatment and glycemic target based on patient factors Should be able to switch to more affordable

More information

Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol

Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed

More information

Advances in Technology in the Treatment of Diabetes Mellitus 2017 How far have we come-how far are we going? Is there a final frontier?

Advances in Technology in the Treatment of Diabetes Mellitus 2017 How far have we come-how far are we going? Is there a final frontier? Advances in Technology in the Treatment of Diabetes Mellitus 2017 How far have we come-how far are we going? Is there a final frontier? Alan B Schorr DO FAAIM FACE www.sugardoc.com abs@sugardoc.com Disclosures

More information

Insulin Prior Authorization with optional Quantity Limit Program Summary

Insulin Prior Authorization with optional Quantity Limit Program Summary Insulin Prior Authorization with optional Quantity Limit Program Summary 1-13,16-19, 20 FDA LABELED INDICATIONS Rapid-Acting Insulins Humalog (insulin lispro) NovoLog (insulin aspart) Apidra (insulin glulisine)

More information

1. Continuous Glucose Monitoring

1. Continuous Glucose Monitoring 1. Continuous Glucose Monitoring 1. Physiology of interstitial fluid glucose 2. Comparison of CGM and self-monitored blood glucose (SMBG) data 3. Insulin dosing indication in BGM vs. CGM & the FDA 4. Protection

More information

CGM Use in Pregnancy & Unique Populations ELIZABETH O. BUSCHUR, MD THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER

CGM Use in Pregnancy & Unique Populations ELIZABETH O. BUSCHUR, MD THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER CGM Use in Pregnancy & Unique Populations ELIZABETH O. BUSCHUR, MD THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER Case 1: CGM use during pregnancy 29 yo G1P0000 at 10 5/7 weeks gestation presents to set

More information

Today s Goals 10/6/2017. New Frontiers in Diabetes Technology. Disclosures

Today s Goals 10/6/2017. New Frontiers in Diabetes Technology. Disclosures New Frontiers in Diabetes Technology Marie E. McDonnell, MD Director, Brigham and Women's Diabetes Program Division of Endocrinology, Diabetes and Hypertension Brigham and Women s Hospital Today s Goals

More information

Diabetes Management: A diagnostic perspective

Diabetes Management: A diagnostic perspective Diabetes Management: A diagnostic perspective Images: http://www.engadget.com/2009/09/23/bayer-introduces-countour-usb-glucose-meter/ http://www.medtronicdiabetes.com/treatment-and-products/minimed-530g-diabetes-system-with-enlite

More information

Application of the Diabetes Algorithm to a Patient

Application of the Diabetes Algorithm to a Patient Application of the Diabetes Algorithm to a Patient Apply knowledge gained from this activity to improve disease management and outcomes for patients with T2DM and obesity Note: The cases in this deck represent

More information

Diabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical

Diabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical Diabetes Technology Continuous Subcutaneous Insulin Infusion Therapy And Continuous Glucose Monitoring In Adults: An Endocrine Society Clinical Practice Guideline Task Force Members Anne Peters, MD (Chair)

More information

Diabetes Meds Update Disclaimer and Important Info. Objectives. Page 1. Copyright , Diabetes Education Services

Diabetes Meds Update Disclaimer and Important Info. Objectives. Page 1. Copyright , Diabetes Education Services Diabetes Meds Update 2016 Beverly Dyck Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Disclaimer and Important Info This content is for educational purposes only. Please see Package

More information

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.

DISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics. DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this

More information

Diabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond)

Diabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond) Diabetes II Insulin pumps; Continuous glucose monitoring system (CGMS) Ernest Asamoah, MD FACE FACP FRCP (Lond) 9501366-011 20110401 Objectives Understand the need for insulin pumps and CGMS in managing

More information

Basal-Bolus Insulin Therapy. Veronica Brady, PhD, FNP-BC, BC-ADM, CDE ECHO January

Basal-Bolus Insulin Therapy. Veronica Brady, PhD, FNP-BC, BC-ADM, CDE ECHO January Basal-Bolus Insulin Therapy Veronica Brady, PhD, FNP-BC, BC-ADM, CDE ECHO January 18 2018 Terminology No longer using the term diabetic. Diabetes does not define people. People with diabetes are individuals

More information

This program applies to Commercial, GenPlus and Health Insurance Marketplace formularies.

This program applies to Commercial, GenPlus and Health Insurance Marketplace formularies. OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) Agonists [Adlyxin (lixisenatide), Byetta (exenatide), Bydureon (exenatide extended-release), Tanzeum (albiglutide), Trulicity (dulaglutide),

More information

Technology in Diabetes Care: Emerging Level

Technology in Diabetes Care: Emerging Level Technology in Diabetes Care: Emerging Level Charlotte Parsons ARNP, CDE Christine Fisher, RD, CD, CDE, CPT WADE April 26, 2019 Disclosures to Participants Notice of Requirements for Successful Completion:

More information

Initiating Injectables in Type 2 Diabetes. Tara Kadis Team Leader Diabetes Nurse Specialist York Teaching Hospital

Initiating Injectables in Type 2 Diabetes. Tara Kadis Team Leader Diabetes Nurse Specialist York Teaching Hospital Initiating Injectables in Type 2 Diabetes Tara Kadis Team Leader Diabetes Nurse Specialist York Teaching Hospital Increasing levels in delivery of diabetes care Complex Care support 3 3.1 People with diabetes

More information

Newer Therapies for Type 2 Diabetes

Newer Therapies for Type 2 Diabetes Newer Therapies for Type 2 Diabetes Sandra Indacochea Sobel, MD Clinical Assistant Professor of Medicine Clinical Chief of Endocrinology, UPMC Mercy Division of Endocrinology, Diabetes, and Metabolism

More information

Diabetes: We ve Come a Long Way, Baby! Amy Wachter, MD Christiana Care Endocrinology March 22, 2018

Diabetes: We ve Come a Long Way, Baby! Amy Wachter, MD Christiana Care Endocrinology March 22, 2018 Diabetes: We ve Come a Long Way, Baby! Amy Wachter, MD Christiana Care Endocrinology March 22, 2018 Title of My Talk Ancient Times Diabetes has been affecting lives for thousands of years. Egyptians in

More information

CASE A2 Managing Between-meal Hypoglycemia

CASE A2 Managing Between-meal Hypoglycemia Managing Between-meal Hypoglycemia 1 I would like to discuss this case of a patient who, overall, was doing well on her therapy until she made an important lifestyle change to lose weight. This is a common

More information

Making the Most of Continuous Glucose Monitoring

Making the Most of Continuous Glucose Monitoring Making the Most of Continuous Glucose Monitoring Gary Scheiner MS, CDE Owner & Clinical Director Integrated Diabetes Services LLC Wynnewood, PA AADE 2014 Diabetes Educator of the Year gary@integrateddiabetes.com

More information

NEW TECHNOLOGIES FOR MANAGING DIABETES ANGELA THOMPSON DNP, FNP-C, BC-ADM, CDE, FAANP

NEW TECHNOLOGIES FOR MANAGING DIABETES ANGELA THOMPSON DNP, FNP-C, BC-ADM, CDE, FAANP NEW TECHNOLOGIES FOR MANAGING DIABETES ANGELA THOMPSON DNP, FNP-C, BC-ADM, CDE, FAANP No commercial support or sponsorship was received for this project I have nothing to disclose OBJECTIVES Identify at

More information

Insulin Management. By Susan Henry Diabetes Specialist Nurse

Insulin Management. By Susan Henry Diabetes Specialist Nurse Insulin Management By Susan Henry Diabetes Specialist Nurse The Discovery of Insulin - 1921 - Banting & Best University Of Toronto Discovered hormone insulin in pancreatic extract of dog - Marjorie the

More information

How I use the latest technology to investigate and treat a person with Type 1 Diabetes. Dr Pratik Choudhary

How I use the latest technology to investigate and treat a person with Type 1 Diabetes. Dr Pratik Choudhary How I use the latest technology to investigate and treat a person with Type 1 Diabetes Dr Pratik Choudhary Disclosures Advisory board and speaker fees from Medtronic, Roche, Abbott and Johnson and Johnson,

More information

The York Diabetes Care Model

The York Diabetes Care Model This Session The York Diabetes Care Model The annual review what s it for and how to do it How to make the diagnosis of diabetes and who to test Categorisation of diabetes at diagnosis Basics of Insulin

More information

LET S TALK INSULIN THE BASICS

LET S TALK INSULIN THE BASICS LET S TALK INSULIN THE BASICS AUTHOR S DISCLOSURES Contracted for program development for Lifescan Canada Speaker for Lifescan, Lilly, BI, Consultant for Lilly, Janssen, Novo Nordisk, Lifescan Canada OBJECTIVES

More information

Hot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care

Hot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care Hot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care Mary Jean Christian, MA, MBA, RD, CDE Diabetes Program Coordinator UC Irvine Health Hot Topics: Diabetes

More information

Newer Insulins. Boca Raton Regional Hospital 15th Annual Internal Medicine Conference

Newer Insulins. Boca Raton Regional Hospital 15th Annual Internal Medicine Conference Newer Insulins Boca Raton Regional Hospital 15th Annual Internal Medicine Conference Luigi F. Meneghini, MD, MBA Professor of Internal Medicine, UT Southwestern Medical Center Executive Director, Global

More information

A Practical Approach to the Use of Diabetes Medications

A Practical Approach to the Use of Diabetes Medications A Practical Approach to the Use of Diabetes Medications Juan Pablo Frias, M.D., FACE President, National Research Institute, Los Angles, CA Clinical Faculty, University of California, San Diego, CA OUTLINE

More information

Clinical Practice Guidelines

Clinical Practice Guidelines Clinical Practice Guidelines Diabetes Objective The purpose is to guide the appropriate diagnosis and management of Diabetes. This guideline is designed to assist the clinician by providing a framework

More information

STEP THERAPY CRITERIA

STEP THERAPY CRITERIA CATEGORY DRUG CLASS BRAND NAME (generic) STEP THERAPY CRITERIA AMYLIN ANALOG: SYMLIN/SYMLINPEN (pramlintide acetate) ANTIDIABETIC AGENTS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1): ADLYXIN (lixisenatide)

More information

8/21/2017 UNRAVELING THE CROWED INSULIN SCENE. A Practical Overview of Insulin Focusing on New Insulin Preparations

8/21/2017 UNRAVELING THE CROWED INSULIN SCENE. A Practical Overview of Insulin Focusing on New Insulin Preparations UNRAVELING THE CROWED INSULIN SCENE A Practical Overview of Insulin Focusing on New Insulin Preparations Patricia Garnica MS, ANP-BC, CDE, CDTC North Shore University Hospital, Manhasset, N.Y. October

More information

Updates in Diabetes Technology

Updates in Diabetes Technology Updates in Diabetes Technology Jessica Kirk, MSN, RN, CPN, CDE Nurse Manager, Endo ECHO No disclosures Disclosures 1 Objectives Distinguish patients appropriate for continuous glucose monitoring and insulin

More information

Diabetes Update 10/12/2017. Section #1 OBJECTIVE. Lab features to consider:

Diabetes Update 10/12/2017. Section #1 OBJECTIVE. Lab features to consider: Section #1 OBJECTIVE Diabetes Update Fall 2017 Lyle Myers BE ABLE TO DIFFERENTIATE TYPE 1 FROM TYPE 2 DIABETES Clinical features: - age at onset - body weight/bmi - family history - treatment history -

More information

NEW DIABETES CARE MEDICATIONS

NEW DIABETES CARE MEDICATIONS NEW DIABETES CARE MEDICATIONS James Bonucchi DO, ECNU, FACE Adult Medicine and Endocrinology Specialists Disclosures Speakers bureau Sanofi AZ BI Diabetes Diabetes cost ADA 2017 data Ever increasing disorder.

More information

!"#$%&%'(!)*+'(,(&)%-!'(.#!%('"./0%(( /1#).!(&2()!(((

!#$%&%'(!)*+'(,(&)%-!'(.#!%('./0%(( /1#).!(&2()!((( !"#%&%'(!)*+'(,(&)%-!'(.#!%('"./0%(( /1#).!(&2()!((( 26%5&"7%'( At the end of this presentation, participants should be able to: Evaluate the emerging role of GLP-1 Agonists for weight loss Understand

More information

The Alphabet Soup of Diabetes. Egils Bogdanovics M.D. Hungerford Diabetes Center

The Alphabet Soup of Diabetes. Egils Bogdanovics M.D. Hungerford Diabetes Center The Alphabet Soup of Diabetes Egils Bogdanovics M.D. Hungerford Diabetes Center Insulin: January 11, 1922 12 year old Leonard Thompson, on a starvation diet for 2 years received his first insulin injection

More information

Objectives. Navigating New Insulins. Disclosures. Diabetes: The Stats. Normal Insulin Release Individuals without diabetes. History of Insulin 5/23/17

Objectives. Navigating New Insulins. Disclosures. Diabetes: The Stats. Normal Insulin Release Individuals without diabetes. History of Insulin 5/23/17 Objectives Compare and contrast currently available products. Navigating New s Diana Isaacs, PharmD, BCPS, BC-ADM, CDE Clinical Pharmacy Specialist Cleveland Clinic Diabetes Center Determine the factors

More information

Complete this CE activity online at ProCE.com/InsulinPart2

Complete this CE activity online at ProCE.com/InsulinPart2 Complete this CE activity online at ProCE.com/InsulinPart2 Case 1: A 67 year old male with T2DM History and Presentation John is a 67 year old retiree who has been visiting your pharmacy/clinic for over

More information

Very Practical Tips for Managing Type 2 Diabetes

Very Practical Tips for Managing Type 2 Diabetes Very Practical Tips for Managing Type 2 Diabetes Jean-François Yale, MD, FRCPC McGill University Health Centre, Montreal, Canada Jean-francois.yale@mcgill.ca www.dryale.ca OBJECTIVES DISCLOSURES The participant

More information

Rhonda Eustice, PharmD, CDE. Will Power lasts about two weeks and is soluble in alcohol. Mark Twain

Rhonda Eustice, PharmD, CDE. Will Power lasts about two weeks and is soluble in alcohol. Mark Twain Rhonda Eustice, PharmD, CDE Will Power lasts about two weeks and is soluble in alcohol. Mark Twain Diabetes Management: The Three Legged Stool Diet Medication Exercise Objectives Know the treatment goals

More information

The ABCs of MDI: Gaining a working knowledge of Multiple Daily Injection insulin therapy. Today s Presenter

The ABCs of MDI: Gaining a working knowledge of Multiple Daily Injection insulin therapy. Today s Presenter FD Title Slide The ABCs of MDI: Gaining a working knowledge of Multiple Daily Injection insulin therapy learn.extension.org/events/3369 3 This material is based upon work supported by the National Institute

More information

Pediatric Diabetes Update Fran R. Cogen, MD, CDE Professor of Pediatrics Director, Diabetes Services

Pediatric Diabetes Update Fran R. Cogen, MD, CDE Professor of Pediatrics Director, Diabetes Services 1.19.18 Pediatric Diabetes Update Fran R. Cogen, MD, CDE Professor of Pediatrics Director, Diabetes Services DISCLOSURES 1. No financial incentives 2. Volunteer Positions 1. National Certification Board

More information

DIABETES & ENDOCRINE DIABETES TECHNOLOGY: HOW TO STAY CURRENT WITH ONGOING TECHNOLOGY ADVANCEMENT

DIABETES & ENDOCRINE DIABETES TECHNOLOGY: HOW TO STAY CURRENT WITH ONGOING TECHNOLOGY ADVANCEMENT DIABETES TECHNOLOGY: HOW TO STAY CURRENT WITH ONGOING TECHNOLOGY ADVANCEMENT Min-Jye Chen, MD Endocrinology Diabetes Management of the School-Aged Child Provided by Texas Children s Hospital Provider #18-267764-A

More information

Update on Insulin-based Agents for T2D

Update on Insulin-based Agents for T2D Update on Insulin-based Agents for T2D Injectable Therapies for Type 2 Diabetes Mellitus (T2DM) and Obesity This presentation will: Describe established and newly available insulin therapies for treatment

More information

Achieving and maintaining good glycemic control is an

Achieving and maintaining good glycemic control is an Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE; Kathleen Wyne, MD, PhD, FACE, FNLA; Anthony Cannon,

More information

Technology in Diabetes Management Irl B. Hirsch, MD University of Washington

Technology in Diabetes Management Irl B. Hirsch, MD University of Washington Technology in Diabetes Management 2016 Irl B. Hirsch, MD University of Washington Dualities Research: Helmsley Charitable Trust, JDRF, ADA, NIDDK, CDC Consulting: Abbott, Roche, Intarcia Raise Your Hand

More information

Ertugliflozin (Steglatro ) 5 mg daily. May increase to 15 mg daily. Take in the morning +/- food. < 60: Do not initiate; discontinue therapy

Ertugliflozin (Steglatro ) 5 mg daily. May increase to 15 mg daily. Take in the morning +/- food. < 60: Do not initiate; discontinue therapy Sodium-glucose Cotransporter-2 (SGLT2) s Inhibit SGLT in proximal renal tubules, reducing reabsorption of filtered glucose from tubular lumen Lowers renal threshold for glucose à increase urinary excretion

More information

Type 2 Diabetes Mellitus: Update on Pharmacotherapy 04/04/18

Type 2 Diabetes Mellitus: Update on Pharmacotherapy 04/04/18 Type 2 Diabetes Mellitus: Update on Pharmacotherapy 04/04/18 No conflicts of interest Objectives for this talk Update on non-insulin drug therapy fro type 2 DM Appropriate use of insulin in type 2 DM ADA

More information

Soliqua (insulin glargine and lixisenatide), Xultophy (insulin degludec and liraglutide)

Soliqua (insulin glargine and lixisenatide), Xultophy (insulin degludec and liraglutide) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.48 Subject: Insulin GLP-1 Combinations Page: 1 of 5 Last Review Date: September 15, 2017 Insulin GLP-1

More information

There have been important changes in diabetes care which may not be covered in undergraduate textbooks.

There have been important changes in diabetes care which may not be covered in undergraduate textbooks. Diabetes Clinical update There have been important changes in diabetes care which may not be covered in undergraduate textbooks. Changes in the diagnosis of diabetes a) HbA1C Since 2011, World Health Organisation

More information

The Realities of Technology in Type 1 Diabetes

The Realities of Technology in Type 1 Diabetes The Realities of Technology in Type 1 Diabetes May 6, 2017 Rosanna Fiallo-scharer, MD Margaret Frederick, RN Disclosures I have no conflicts of interest to disclose I will discuss some unapproved treatments

More information

Insulin Pump Therapy in children. Prof. Abdulmoein Al-Agha, FRCPCH(UK)

Insulin Pump Therapy in children. Prof. Abdulmoein Al-Agha, FRCPCH(UK) Insulin Pump Therapy in children Prof. Abdulmoein Al-Agha, FRCPCH(UK) aagha@kau.edu.sa Highlights Evolution of insulin pump Pumps mimics Pancreas Goals of diabetes care What lowers HbA1c Criteria for selection

More information

FARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)

FARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin) Type 2 Medications Drug Class How It Works Brand and Generic Names Manufacturers Usual Starting Dose The kidneys filter sugar and either absorb it back into your body for energy or remove it through your

More information

Diabetes Management: Current High Tech Innovations

Diabetes Management: Current High Tech Innovations Diabetes Management: Current High Tech Innovations How Far We ve Come in the Last 40 Years William V. Tamborlane, MD Department of Pediatrics Yale School of Medicine Disclosures I am a consultant for:

More information

Starting and Helping People with Type 2 Diabetes on Insulin

Starting and Helping People with Type 2 Diabetes on Insulin Starting and Helping People with Type 2 Diabetes on Insulin Elaine Cooke, BSc(Pharm), RPh, CDE Pharmacist and Certified Diabetes Educator Maple Ridge, BC Objectives After attending this session, participants

More information

DIABETES (1 of 5) Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10. Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10 $0 $0 $0

DIABETES (1 of 5) Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10. Generic. Generic $0 $5 $5-10 $0 $0 $0. Generic $0 $5 $5-10 $0 $0 $0 Metformin DIABETES (1 of 5) Glucophage Glucophage XR ER $7 (500mg) $7 (500mg) $5 $5 500mg, 750mg only 500mg, 750mg only Sulfonylurea/Combinations Amaryl Glucotrol glimepiride glipizide $5 $5 Glucotrol

More information

Antihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014

Antihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014 Antihyperglycemic Agents in Diabetes Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014 Objectives Review 2014 ADA Standards of Medical Care in DM as they

More information

New Drug Evaluation: Insulin degludec/aspart, subcutaneous injection

New Drug Evaluation: Insulin degludec/aspart, subcutaneous injection New Drug Evaluation: Insulin degludec/aspart, subcutaneous injection Date of Review: March 2016 End Date of Literature Search: November 11, 2015 Generic Name: Insulin degludec and insulin aspart Brand

More information